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Abstract
Background  and  objectives:  management  of  pain  in  painful  blind  eyes  is  still  a  challenge.  Cor-
ticosteroids  and  hypotensive  agents,  as  well  as  evisceration  and  enucleation,  are  some  of  the
strategies  employed  so  far  that  are  not  always  effective  and,  depending  on  the  strategy,  cause
a deep  emotional  shock  to  the  patient.  Given  these  issues,  the  aim  of  this  case  report  is  to
demonstrate  a  new  and  viable  option  for  the  management  of  such  pain  by  treating  the  painful
blind eye  with  the  stellate  ganglion  block  technique,  a  procedure  that  has  never  been  described
in the  literature  for  this  purpose.
Case  report:  six  patients  with  painful  blind  eye,  all  caused  by  glaucoma,  were  treated;  in  these
patients,  VAS  (visual  analogue  scale  for  pain  assessment,  in  which  0  is  the  absence  of  pain  and
10 is  the  worst  pain  ever  experienced)  ranged  from  7  to  10.  We  opted  for  weekly  sessions
of stellate  ganglion  block  with  4  mL  of  bupivacaine  (0.5%)  without  vasoconstrictor  and  cloni-
dine 1  mcg/kg.  Four  patients  had  excellent  results  at  VAS,  ranging  between  0  and  3,  and  two
remained  asymptomatic  (VAS  =  0),  without  the  need  for  additional  medication.  The  other  two
used gabapentin  300  mg  every  12  h.
Conclusion:  currently,  there  are  several  therapeutic  options  for  the  treatment  of  painful  blind
eye, among  which  stand  out  the  retrobulbar  blocks  with  chlorpromazine,  alcohol  and  phenol.
However, an  effective  strategy  with  low  rate  of  serious  complications,  which  is  non-mutilating
and improves  the  quality  of  life  of  the  patient,  is  essential.  Then,  stellate  ganglion  block  arises
as a  demonstrably  viable  and  promising  option  to  meet  this  demand.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.∗ Corresponding author.
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Dor  ocular;
Manejo  da  dor;
Bloqueio  nervoso
Tratamento  de  pacientes  portadores  de  olho  cego  doloroso  por  meio  de  bloqueio  de
gânglio  estrelado
Resumo
Justiﬁcativa  e  objetivos:  O  manejo  da  dor  em  olhos  cegos  dolorosos  ainda  é  um  desaﬁo.  Corti-
costeroides  e  hipotensores,  bem  como  eviscerac¸ão  e  enucleac¸ão,  são  algumas  das  estratégias
até então  empregadas,  nem  sempre  eﬁcazes  e  que,  a  depender  da  estratégia,  causam  um  pro-
fundo abalo  emocional  no  paciente.  Dadas  essas  questões,  o  objetivo  deste  relato  de  caso  é
demonstrar  uma  nova  e  viável  opc¸ão  para  o  manejo  desse  tipo  de  dor  por  meio  do  tratamento
do olho  cego  doloroso  com  bloqueios  de  gânglio  cervicotorácico,  técnica  nunca  descrita  na
literatura para  esse  ﬁm.
Relato  de  caso:  Foram  tratados  seis  pacientes  portadores  de  olho  cego  doloroso,  todos  por
glaucoma,  nos  quais  a  EVA  (escala  visual  analógica  para  avaliac¸ão  da  dor  em  que  0  é  ausência
de dor  e  10  é  a  maior  dor  já  experimentada)  variava  de  7  a  10.  Optou-se  por  sessões  semanais
de bloqueio  de  gânglio  cervicotorácico  com  4  mL  de  bupivacaína  (0,5%)  sem  vasoconstritor  e
clonidina 1  mcg/Kg.  Quatro  pacientes  apresentaram  excelente  resultado  EVA,  com  variac¸ão
entre 0  e  3,  e  dois  permaneceram  assintomáticos  (EVA  =  0),  sem  necessidade  de  medicac¸ão
suplementar.  Os  outros  dois  usaram  gabapentina  300  mg  de  12  em  12  horas.
Conclusão:  Atualmente,  várias  são  as  opc¸ões  terapêuticas  para  o  tratamento  do  olho  cego
doloroso, entre  as  quais  se  destacam  os  bloqueios  retrobulbares  com  clorpromazina,  álcool
e fenol.  No  entanto,  uma  estratégia  eﬁcaz,  com  pequeno  índice  de  complicac¸ões  graves,  não
mutilante e  que  melhore  a  qualidade  de  vida  do  paciente  é  imprescindível.  O  bloqueio  do
gânglio cervicotorácico  surge,  pois,  como  uma  opc¸ão  comprovadamente  viável  e  promissora
para atender  a  essa  demanda.
©  2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
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ntroduction
anagement of pain in painful blind eyes is still a challenge and
epresents one of the most frustrating problems in ophthalmol-
gy. For years, numerous therapeutic strategies were tempted, with
he aim to relieve ocular pain symptoms. Corticosteroids, hypoten-
ive drugs and therapeutic contact lenses have proved useful in
ome cases. Evisceration and enucleation1 tend to be proposed in
ore treatment-resistant cases. However, these latter options are
esponsible for a deep emotional shock to the patient, and with
espect to the evisceration, it does not always promote full pain
elief. Retrobulbar injections with neurolytic agents and chlorprom-
zine constitute the most widespread therapeutic strategies,2 but
ften cause signiﬁcant complications, such as permanent paralysis
f ocular muscles, retrobulbar haemorrhage, optic nerve atrophy
nd perforation of the globe. The case report in question con-
erns the choice of a new therapeutic strategy for the treatment of
ainful blind eye, where the stellate ganglion blockade was used --
 technique not described in the literature for this purpose.
ase  report
he subjects were six patients with painful blind eye caused by
laucoma, in whom the treatment with topical agents and special
ontact lenses introduced by ophthalmology did not succeed. Ini-
ial evaluation of these patients showed that the self-described
ain intensity ranged from 7 to 10 in VAS (visual analogue scale),
hich signiﬁcantly compromised their daily activities. A course of
ix weekly sessions of cervicothoracic (stellate) ganglion block with
 mL of 0.5% bupivacaine without vasoconstrictor and clonidine
 mcg Kg−1 was proposed. These sessions were performed in the
urgical suite, with blocking by paratracheal route.
p
e
K
cesults
 year has passed since the beginning of treatment until ambulatory
ischarge. Four patients showed excellent response to treatment;
wo of them remained completely asymptomatic, with no need
or additional medication, and two remained with residual pain
elf-characterized as VAS 3. These latter patients continued
reatment with gabapentin 300 mg every 12 h. With respect to the
ther two patients, one of them abandoned the clinic after the
locks and the other presented major depression concomitant to
er eye pain, and was found drunk in two of the consultations,
actors that greatly compromised her treatment. At that time,
he patient was medicated with carbamazepine 200 mg  every 8 h,
orphine sulphate 10 mg every 4 h, sertraline 150 mg once daily
nd nortriptyline 75 mg once a day.
iscussion
ccording to Bonica,3 ophthalmic pain is characterized by its
ntensity and ability to generate anxiety. Second only to fear of
eath, the fear of blindness involves a great emotional charge to
he patient and to his/her doctor. Thus, adequate attention should
e given to eye pain, not only for patient comfort, but also for
revention and treatment of those patients with narrow-angle
laucoma, in which the extent of structural and functional damage
s closely related to the duration of the pain crisis. Glaucoma can
e characterized as a optic neuropathy associated with a typical
ptic nerve damage.4 Then, the possibility arises that part of the
lind glaucomatous eye pain might be explained by this optic neu-
opathy and by the structural damage responsible for neuropathic
ain.5,6 This hypothesis -- that the pain in blind and glaucomatous
yes could be of neuropathic origin -- was ﬁrst approached by
avaliteratos7 in a case report in which a patient with that
ondition was treated with gabapentin, with excellent response.
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Neuropathic  pain  and  sympathetic  nervous  system
Studies show that allodynia and hyperalgesia appear to involve both
the central and the peripheral nervous system. Neuropathic pain of
peripheral tissues is generated or maintained exclusively by sensory
nerves, or by aberrant actions of the sympathetic nervous system
in sensory nerves.8
It is already known that peripheral nerve injuries provide plas-
tic changes, both of primary afferent neurons and sympathetic
postganglionic neurons, depending on the type (partial or total)
of injury. This neuronal plasticity is characterized by degenerative
and regenerative changes and by rearrangements culminating in
biochemical links among primary afferent and postganglionic sym-
pathetic neurons, as well as in collateral links in the dorsal root
ganglion by intact neurons. These links are responsible for the
activation of primary afferent neurons by the sympathetic nervous
system, in which the likely mediator is norepinephrine.9
Thus, one can infer that part of the eye pain has as its main-
tainer the sympathetic nervous system, though this is not its primary
cause. The pain maintained by the sympathetic nervous system
is characterized by a burning sensation, allodynia, and cold and
touch hyperalgesia,10 symptoms presented by patients treated in
the present case report. Numbness and hyperesthesia are common
and there may be swelling and other signs of autonomic dysfunction.
Strategies  for  eye  pain  treatment
Through the years various strategies have been developed for the
treatment of ocular pain. Gruter in 1918 described his experience
with retrobulbar injections of alcohol.11,12 After this investigator,
several others described their experiences, some also with the use
of phenol replacing alcohol. Both are neurolytic agents still used,
but which have been abandoned in some centres as they have lim-
ited analgesic effect (around three months) and their use may cause
signiﬁcant complications, such as retrobulbar haemorrhage, perma-
nent paralysis of eye muscles and permanent ptosis.
Currently the most widespread technique has been the use of
retrobulbar injections of chlorpromazine,13 ﬁrst suggested in 1980
by Fiore and in 1989 by Bastrikof, with reported pain relief in 84% of
patients in the studies.14 However, this is a technique with limited
duration, around six months. In addition, there are reports of block
technique failure, as well as signiﬁcant side effects such as oedema,
ptosis, sterile orbital cellulitis, transient limitation of extraocular
movements, retrobulbar haemorrhage and corneal epithelial injury,
among others.
Enucleation and evisceration are also options for the cases
in which pain is debilitating and does not respond to any of the
mentioned treatments. Especially in cases of eye disﬁguration, evis-
ceration and enucleation end up being the treatments of choice.15
It should be borne in mind the deep emotional harm that occurs in
patients who undergo this technique, especially in cases where the
eye, although painful, was looking good. In addition, there is the
fact that enucleation is not always effective, because the cilliary
nerves may remain intact and thus convey a residual pain.
Stellate  ganglion  block
Usually, the stellate ganglion is formed by the fusion of the infe-
rior cervical and ﬁrst thoracic ganglia, being responsible for most
of the sympathetic innervation of the head, neck and arm. Its block
has been described as therapeutic for various disorders. There are
reports of treatment for glaucoma and facial pain with the use of
this type of block.6,16,17 The treatment of orofacial pain with stel-
late ganglion block has been well reported in the literature, withion  block  77
espect to the well-known involvement of the sympathetic nervous
ystem in this type of pain.18 In 1953, Miller showed that the block-
ng of this ganglion alters the intraocular pressure in glaucomatous
yes.19 However, the treatment of painful post-glaucoma blind eye
ith stellate ganglion block has never been described in the litera-
ure.
onclusion
he treatment of painful blind eyes is controversial and poorly
ddressed in the literature. Among the various therapeutic options,
tellate ganglion block can be a viable and promising proposal.
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